This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

ATRA in acute promyelocytic leukaemia trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This trial compared disease-free survival and overall survival in patients with previously untreated acute promyelocytic leukaemia who were randomised to ATRA+chemotherapy or chemotherapy alone.

346 patients were randomised to one of two protocols:

  • ATRA induction:
    • ATRA as induction treatment
    • patients in complete remission underwent another cycle of ATRA treatment
    • high dose daunorubicin and cytarabine
    • patients still in complete remission were randomised to maintenance with ATRA or observation

  • chemotherapy induction:
    • daunorubicin and cytarabine induction
    • patients in complete remission had another cycle of chemotherapy
    • high dose daunorubicin and cytarabine
    • patients still in complete remission were randomised to maintenance with ATRA or observation

Results:

  • ATRA and chemotherapy were equally effective as induction agents
  • disease-free survival was higher in regimens containing ATRA
  • overall survival was higher in regimens containing ATRA

Reference:

  • Tallman, MS. et al. (1997). All-trans-retinoic acid in acute promyelocytic leukaemia. New Engl. J. Med. 337, 1021-8.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.